Pancreatic cancer (PC) incidence rates are rapidly increasing in developed countries, with half the patients being metastatic at diagnosis. For decades, fluorouracil, then gemcitabine regimens were the preferred palliative first-line options for fit patients with metastatic PC. FOLFIRINOX (a combination of bolus and infusional fluorouracil, leucovorin, irinotecan and oxaliplatin) was introduced to clinical practice in 2010 due to the results of the phase II/III trial (PRODIGE 4/ACCORD 11) comparing FOLFIRINOX with singleagent gemcitabine as first-line treatment for patients with MPC. Median overall survival, progression-free survival, and objective response rate were superior with FOLFIRINOX over gemcitabine and there was prolonged time to definitive deterioration in quality of life. Although FOLFIRINOX was also associated with increased toxicity, mainly febrile neutropenia and diarrhea, there has been rapid uptake of this regimen. This review closely examines optimal management and prevention of toxicities, international recommendations for firstline treatment, and use of modified FOLFIRINOX protocols. In this review, we also look at the potential benefit of FOLFIRINOX in selected groups of patients: second-line therapy, adjuvant chemotherapy, induction therapy in patients with borderline resectable and locally advanced PC. Robust validation of the FOLFIRINOX regimen in these settings requires confirmation in further randomized trials.
Introduction: actual situation
Pancreatic ductal adenocarcinoma is a major cause of cancer-related mortality in western countries and projected to emerge as the second leading cause of cancer-related deaths in the US by 2030. 1 Its prognosis remains extremely poor, with a 5-year survival rate of just 8%. 2 The only potential curative therapy is surgical resection; however, as little as 10-15% of patients with pancreatic cancer (PC) are eligible. At diagnosis, 52% of PC cases are stage IV. 2 These patients may be candidates for systemic chemotherapy with the aim of prolonging survival, reducing symptoms and either maintaining or increasing quality of life (QoL). In this review, we aimed to update knowledge about the use of the FOLFIRINOX regimen in routine practice taking into account pharmacoeconomic data and future developments. Finally, we tried to clarify the best options in first-line and second-line in patients with metastatic PC (MPC).
For decades, fluorouracil was the most common chemotherapy agent in advanced PC until the 1997 approval of gemcitabine. Single-agent gemcitabine has since been the standard palliative treatment as it significantly increased the 'clinical benefit response' compared with bolus fluorouracil in a landmark randomized phase II study. 3 Gemcitabine also slightly increased median survival from 4.4 to 5.7 months (p = 0.0025). Moreover, gemcitabine was well tolerated, with few severe effects. Thereafter, many targeted or cytotoxic agents in combination with gemcitabine failed to show any improvement in either overall survival (OS) or QoL. 4 The only exception being erlotinib, which provided a statistically significant, although clinically irrelevant, median OS benefit of 10 days in combination with gemcitabine. 5 The FOLFIRINOX regimen (a combination of bolus and infusional fluorouracil, leucovorin, irinotecan and oxaliplatin) has since emerged to significantly advance treatment of MPC. Both the safety and efficacy of FOLFIRINOX were first indicated in a phase II study performed by the UNICANCER gastrointestinal group in patients with locally advanced or MPC. 6 This study reported a response rate (RR) of 26% [95% confidence interval (CI), 13 -39%] and a promising median OS of 10.2 months, with no toxic deaths. However, 52% of patients experienced a severe neutropenia and 4% a grade 4 febrile neutropenia. The EORTC QLQ-C30 assessed QoL data revealing a 10-point improvement in either a functional or symptom scale in 42-69% of patients. Responders demonstrated a major improvement in their global QoL scores (>25 points). 6 Phase III trials in metastatic pancreatic cancer Following this encouraging data, we conducted a phase II/III trial (PRODIGE 4/ACCORD 11) comparing FOLFIRINOX with single-agent gemcitabine as first-line treatment of patients with MPC in France. 7 The trial used OS as primary objective, and progression-free survival (PFS), QoL, RR and toxicity as secondary endpoints. A total of 342 patients were enrolled. Trial entry was restricted to patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 given one previous trial, suggesting a possible benefit from combination chemotherapy was limited to patients with a Karnofsky score of 90 or 100. 8 Other eligibility criteria included age under 76, bilirubin below 1.5 times the upper limit of normal, measurable MPC and adequate organ function. Treatment of 6 months was recommended for responding patients. No granulocyte-colony stimulating factor (G-CSF) was permitted as primary prophylaxis of neutropenia. Assessment of tumor response occurred every 8 weeks, using a CT scan with contrast.
The trial began as a randomized phase II study using RR as a primary endpoint. Following an independent review confirming an objective RR of 34.1% in the FOLFIRINOX group and 11% in the gemcitabine group, the trial then proceeded to phase III. The study design enabled an 80% power for detecting an increase in median OS from 7 to 10 months (HR = 0.70, α = 0.05). The final analysis required 360 patients to reach 250 events. At the preplanned interim analysis after 167 events, the study achieved its primary endpoint with a p-value < 0.001; therefore the independent data monitoring committee recommended termination of accrual.
A total of 342 patients from 48 French centers had enrolled into the study. Compared with treatment with gemcitabine, the FOLFIRINOX regimen resulted in a superior objective RR (9.4 versus 31.6 %; p < 0.001). The median number of months on treatment was 5 (range: 0.5-23.5) in the FOLFIRINOX group and 3 (range: 0.5-13) in the gemcitabine group (p < 0.001). Analysis also revealed a median duration of response of 5.9 and 3.9 months in the FOLFIRINOX and gemcitabine groups, respectively (p = 0.57 The main results from a confirmatory phase III trial performed in India with the same study design are available as an abstract. 10 A total of 310 patients with an ECOG PS score of 0 or 1 were randomized to receive either FOLFIRINOX or gemcitabine using the Burris schedule. They reported a median OS of 10.8 months in the FOLFIRINOX group compared with 7.4 months in the gemcitabine group (HR, 0.48; p < 0.001). Median PFS was 5.6 months in the FOLFIRINOX group versus 3.1 months in the gemcitabine group (HR, 0.44; p < 0.001). The FOLFIRINOX group reported an objective RR of 29.6% compared with 8.3% for the gemcitabine group. At 6 months, 29% of patients in the FOLFIRINOX group showed a definitive degradation in their QoL versus 59% of the gemcitabine group (HR, 0.45; p < 0.001).
Real-world view
Many prospective and retrospective studies have confirmed the ACCORD 11 data in terms of OS, PFS and safety. [11] [12] [13] [14] Consequently, the FOLFIRINOX regimen is recommended by the main international guidelines as the standard of care in those patients who are fit, with a good PS and no major comorbidities. Therefore, the National Comprehensive Cancer Network, American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) guidelines recommend FOLFIRINOX for metastatic pancreatic adenocarcinoma (MPA) patients with either 0 or 1 ECOG PS and a favorable comorbidity profile. [15] [16] [17] [18] [19] [20] All guidelines state the mandatory assessment of patients in terms of their condition and comorbidities in order to offer appropriate treatment with a safe toxicity profile. Despite this, the FOLFIRINOX regimen exhibits a specific profile of toxicity among distinct populations. Okusaka et al. conducted a phase II study among chemotherapy-naïve Japanese patients 21 with RR as the primary endpoint. A total of 36 patients enrolled between June 2011 and September 2012, with a median age of 61.5 years and an ECOG of 0 or 1. The trial involved a median number of eight cycles and reported a median OS of 10.7 months, a median PFS of 5.6 months and an RR of 38.9% (95% CI, 23.1-56.5). The toxicity profile of FOLFIRINOX appeared less favorable in this study, especially in terms of hematological side effects: 28 patients (77.8%) experienced grade 3 or 4 neutropenia with febrile neutropenia observed in eight patients (22.2%). Consequently, dose reduction or cycle delay occurred in 89% of the patients. The use of fulldose FOLFIRINOX regimen therefore requires careful consideration in specific Japanese populations. However, in 2013, this combination therapy was approved for unresectable PC in Japan.
Also of concern in daily practice is care of the elderly. The median age at enrollment was 61 in the ACCORD 11 FOLFIRINOX arm, however, Baldini et al. focused on the specific population of elderly patients. 22 Between 2008 and 2015, their retrospective chart review enrolled 42 patients with a median age of 73 (70-79), good PS (ECOG PS 0-1: 93%) and few comorbidities (median Charlson index = 10). Most patients (88%) presented with metastatic disease. Dose reductions occurred at the discretion of the treating physician, so from the first cycle, 57% of the patients received a primary dose reduction. The FOLFIRINOX regimen was most frequently prescribed after 2011 (37/42 patients, 88%). This study reported data consistent with the ACCORD 11 trial, with a median OS of 12.6 months. Moreover, reducing the primary dose appeared to have no significant effect on OS: 11.7 months (6.9-16.4) compared with 16.6 months (0.37-32.8), p = 0.69. Although toxicity was manageable, 54% of all grade neuropathy reached grade 3 for almost half of patients. The sepsis and septic shock rates appeared quite low, consistent with primary dose reduction and primary G-CSF prophylaxis used in 33% of patients. Currently, an ongoing phase II prospective French trial, PAMELA-70, is assessing the safety and efficacy of dose-adjusted FOLFIRINOX in elderly patients with MPA [ClinicalTrials.gov identifier: NCT02143219]. The irinotecan dose will be adjusted according to the UGT1A1 status and the 5-fluorouracil dose according to the dihydropyrimidine dehydrogenase pharmacogenetic status.
First-line regimen options for patients with metastatic pancreatic cancer
The current standard of care for MPC patients with a good PS is either FOLFIRINOX or gemcitabine plus nanoparticle albumin-bound (nab)paclitaxel (GnP). 17 To our knowledge, no head-to-head clinical trials comparing these two new regimens have been published and interstudy comparisons are inherently limited. The main results of the two pivotal trials are presented in Table 1 . Some authors argue that different populations in the phase III pivotal trials of these combinations may have influenced more favorable results of FOLFIRINOX. 23, 24 The main difference between the trials is PS in the inclusion criteria: the FOLFIRINOX trial registered patients with an ECOG PS of 0 or 1, whereas the MPACT trial allowed a Karnofsky PS of 70 corresponding to a PS of 2. 25 Patients classified as Karnofsky 70 (7.6%) 26 demonstrated a median OS of 3.9 months in the GnP group and 2.8 months in the gemcitabine group. 27 In both randomized trials, the two treatment groups showed similar demographic and clinical characteristics at baseline. Although the MPACT and ACCORD 11 trials reported similar median ages, no specified age limit for inclusion existed in the MPACT trial, with 10% of patients older than 75-years old. Both trials included identical control arms: gemcitabine as monotherapy 1000 mg/m² prescribed weekly for 7 weeks followed by treatment on days 1, 8 and 15, every 4 weeks. Both randomized trials reported identical median OS in the gemcitabine group of 6.8 months 7 and 6.7 months, 26 suggesting that both study populations consisted of similar prognostic factors.
Gemcitabine is an appropriate treatment option for patients who choose to receive less-toxic therapy, and those who have either an ECOG PS of 2, or a comorbidity profile, precluding the use of combination chemotherapy. 17
Benefit-risk balance and pharmacoeconomic analysis
The benefit-risk balance has previously been assessed using a generalized pairwise comparison based on prioritized outcomes: OS, PFS and grade 3-4 adverse events. The main analysis of benefit risk balance, as well as all sensitivity analyses, revealed a strong preference towards the FOLFIRINOX regimen. 28 In Canada, the cost effectiveness of first-line FOLFIRINOX was compared with first-line gemcitabine in MPC patients to submit to Ontario public decision makers. Results of the Markov analytical decision model revealed FOLFIRINOX as cost effective, especially with the reducing drug costs of using generic drugs. 29 A second Markov model compared single-agent gemcitabine with gemcitabine-capecitabine, gemcitabine-erlotinib and FOLFIRINOX. 30 Tariffs from nine different countries revealed differences in quality-adjusted life years (QALY) and incremental cost-effectiveness ratio (ICER) between countries with a willingness-to-pay threshold of $50,000. Gemcitabine showed the highest probability as a cost-effective treatment for all countries with a higher willingness-to-pay threshold (>$150,000), whereas FOLFIRINOX appeared as the treatment most likely to be cost effective using any of the country indices. 30 A Markov model also analyzed GnP, FOLFIRINOX, and gemcitabine as first-line treatment from an economic payer perspective in the US. 23 31 another Canadian analysis revealed FOLFIRINOX as cost effective, with an ICER below commonly quoted ICER thresholds for oncology products. Since then, the cost of oxaliplatin has considerably reduced, particularly as generic oxaliplatin is available almost worldwide. This must be weighed up by the fact that most North American physicians use G-CSF or pegfilgrastim prophylaxis 32 despite a febrile neutropenia risk far below the 20% cutoff of ASCO guidelines for primary prophylaxis, and no evidence-based DFS or OS benefit in secondary prophylaxis as compared with reduced doses or treatment delay; thus was not included into most of the economic models.
Furthermore, using the 2015 Canadian reduced costs ($549 for FOLFIRINOX and $4431 for GnP over 4 weeks), FOLFIRINOX is cost effective compared with GnP. 33 Overall, this analysis concluded FOLFIRINOX as the optimal regimen on the basis of cost and QALY. On the other hand, we must consider that drug prices account for only a part of the cost of delivering chemotherapy. The time spent in an infusion chair and the added cost of the ambulatory infusion pump for delivery of 5-FU must be considered. For example, the chair time for GnP is substantially less but at the price of less efficiency. Finally, the attractive price of the FOLFIRINOX regimen must be counterbalanced by the cost of supportive care (antiemetics, antidiarrheals, etc.) sometimes required. Those factors were integrated in the Goldstein et al. review. As expected, the treatment cost variability depends on the use of both GnP and growth factor. 34 Only a real-world claims database study might shed light on this issue.
Maintenance therapy after first-line FOLFIRINOX
Oxaliplatin neurotoxicity is often limiting and certain patients in the ACCORD 11 study received prolonged treatment without oxaliplatin over the planned 12 cycles. A maintenance strategy provides another option to delay deterioration of QoL in patients with controlled disease. A study of 30 patients retrospectively evaluated a continuous maintenance strategy with capecitabine until progression after four-to-eight cycles of FOLFIRINOX. This single-institution study suggested partial efficacy in selected patients treated with capecitabine, with a median PFS of 5 months and a median OS of 17 months. FOLFIRINOX reintroduction occurred in 45% of patients. 35 The PRODIGE 35/PANOPTIMOX phase II randomized trial [ClinicalTrials.gov identifier: NCT02352337] assessed the role of maintenance chemotherapy with fluorouracil and leucovorin (LV5FU2 regimen). The three treatment arms included: (i) FOLFIRINOX until progression; (ii) eight cycles of FOLFIRINOX followed by LV5FU2 until progression, or (iii) 2 months of FOLFIRINOX followed by 2 months of gemcitabine until progression. This trial recently completed accrual and we await results.
FOLFIRINOX as second-line treatment
A randomized trial assessing chemotherapy versus best supportive care has shown that certain patients benefit from a second-line treatment. 36 FOLFIRINOX as a second-line therapy in patients with MPA has been evaluated in a few small retrospective studies involving patients treated with a gemcitabine-based regimen. For example, in an exploratory analysis of the MPACT trial, FOLFIRINOX after GnP resulted in the longest OS of all second-line treatments analysed. However, FOLFIRINOX was given to patients with better PS. 37 A French study including 27 patients showed that the FOLFIRINOX regimen could be safely used as second-line therapy, with partial anticancer activity: 5/27 (19%) achieved partial responses, with a median PFS and OS of 5.4 months (0.5-25.5) and 8.5 months (0-26), respectively. 38 Another survey revealed an objective RR of 27.8% and a disease control rate of 55.6%, 39 however, the median PFS was 2.8 months. This short PFS suggests that FOLFIRINOX may be more appropriate as first-line chemotherapy. A single-institution experience Japanese study including 13 patients with an ECOG PS of 0 or 1 and no major comorbidities, compared pretreatment with either gemcitabine or S-1, or a combination of both. In the study, 4 out of 13 patients (30.8%) achieved a partial response and data revealed a median PFS and median survival of 4.7 months and 6 months, respectively. 40 In our opinion, it would be unethical to launch a strategic phase III trial comparing two successive lines of chemotherapy, especially if determining the best sequence of gemcitabine as a single agent versus FOLFIRINOX, as the PS of patients can rapidly decline after tumor progression in PC. Moreover, the controversial data on oxaliplatin/fluorouracil as second-line treatment perhaps suggests that the benefit from oxaliplatinbased chemotherapy is suitable only as first-line therapy. 41 Until now, there is no clear standard treatment strategy for second-line therapy in advanced PC. 42
Second-line treatment after first-line FOLFIRINOX
There are very little data and no established evidence regarding second-line chemotherapy in patients with MPC progressing on first-line FOLFIRINOX and therapy options are limited. A retrospective survey involving 20 patients reported data on gemcitabine as second-line therapy after progression on FOLFIRINOX. It reported a median PFS and OS of 2.0 months and 5.7 months, respectively. These results are very similar to those obtained with gemcitabine as first-line treatment. 43 To our knowledge, there are no published data on the use of nanoliposomal irinotecan in combination with fluorouracil in this setting. A single-institution retrospective study involving 28 patients evaluated second-line GnP and reported a median PFS and median OS of 2.8 months and 5.3 months, respectively. Five patients (17.9%) achieved a partial response. Toxicities were mild. The authors suggest no effect of first-line FOLFIRINOX on limiting the use or compromising efficacy of second-line GnP. 44 GnP has also been evaluated in a prospective study involving 57 patients. Objective responses occurred in 10 patients (17.5%) with a disease control of 58%. Median PFS was an encouraging 5.1 months, with a median OS of 8.8 months. 45 According to the ASCO clinical practice guidelines, GnP may be an appropriate option for second-line therapy in patients who experience disease progression following first-line treatment with FOLFIRINOX. 17, 45 Single-agent gemcitabine or inclusion into a clinical trial may also be considered for patients with a well-preserved PS. 46
How important are modifications to the FOLFIRINOX regimen?
In the phase III ACCORD-11 trial, 7 FOLFIRINOX (oxaliplatin 85 mg/m 2 , irinotecan 180 mg/m 2 , leucovorin 400 mg/m 2 , and fluorouracil given as a bolus of 400 mg/m 2 followed by a 46-h continuous infusion of 2,400 mg/m 2 given every 2 weeks) significantly increased grade 3 or higher neutropenia compared with single-agent gemcitabine (45.7% versus 21%), as well as febrile neutropenia (5.4 versus 1.2%), thrombocytopenia, diarrhea, and neuropathy.
Modified FOLFIRINOX (mFOLFIRINOX) typically consists of reduced irinotecan or suppression of the bolus fluorouracil, or sometimes both. Although many retrospective and thorough prospective pilot studies have been reported, no randomized trial evaluating mFOLFIRINOX has been conducted. Major recent studies are reported in Table 2 .
Regardless of the efficacy related to OS and PFS, the FOLFIRINOX regimen is associated with less toxicity, especially hematological toxicities. However, there are still some patients who experience febrile neutropenia, although the main toxicities are easily manageable in routine practice. Despite the heterogeneity of dose-reduction protocols, the great majority of these studies show comparable efficacy and OS data with the phase III ACCORD 11 trial. Alternative mFOLFOXIRI regimens using irinotecan first (instead of oxaliplatin first in the FOLFIRINOX regimen) have been tested in advanced PC. In their observational cohort study, the GONO group showed a comparable RR of 38.6% and OS of 10.8 months using FOLFORIXI and mFOLFOXIRI regimens in locally advanced and metastatic PC and concluded that it was a suitable alternative to FOLFIRINOX. 47
Management of toxicities
Dosage adjustment guidelines for FOLFIRINOX toxicities are available in the supplementary appendix of the pivotal study online. 7 FOLFIRINOX should be considered as a highly emetogenic chemotherapy due to oxaliplatin and warrants optimal prophylaxis of nausea/vomiting. As in routine practice, reducing a patient's drug dose is a standard approach in cases of toxicity. Retrospective single-institution series from highly selected academic centers have confirmed the safety of FOLFIRINOX in patients with indwelling biliary stents and successful biliary drainage. 48 Recommendations for the management and prevention of the most frequent toxicities are shown in Table 3 . There are no differences in the use of oxaliplatin, irinotecan and fluorouracil in MPC and colorectal cancer, for either FOLFIRI or FOLFOX common regimens. Transient dysarthria and blepharospasm are rare toxicities of irinotecan infusion, first recognized during the FOLFIRINOX infusion by Gunturu et al. 49 Japanese investigators observed no cases of dysarthria in clinical trials of FOLFOXIRI in advanced colorectal cancer. 50 In this regimen, irinotecan is administered prior to oxaliplatin. They suggested that the FOLFIRINOX-induced dysarthria may be associated with the sequence of drug administration: intravenous infusion of oxaliplatin, immediately followed by leucovorin, followed by 30 min irinotecan. However, in vitro data suggest that cytotoxicity was maximal when oxaliplatin was administered prior to SN-38, 51 the active metabolite of irinotecan; therefore we do not recommend the use of irinotecan prior to oxaliplatin except in cases of dysarthria. 
Future directions of FOLFIRINOX use
In patients with resectable PC, the current standard of care is curative surgery followed by 6 months of adjuvant chemotherapy with gemcitabine or fluorouracil plus leucovorin. However, despite macroscopically curative resection, the long-term results At diagnosis, borderline resectable PC (BRPC) includes tumors involving the mesenteric vasculature to a limited extent, and those eligible for resection yet likely to be compromised by positive surgical margins (R1) in the absence of induction treatment. Although radiographically localized, they are often associated with subclinical metastases. Induction treatment of BRPC aims to reduce tumor volume prior to surgery in order to improve the chances of radical (R0) resection and reduce the rate of lymph node positivity and recurrences. The FOLFIRINOX regimen as upfront chemotherapy has been evaluated in this setting in many case series 52 and appears to be a well-tolerated and promising treatment for patients with BRPC. A meta-analysis, specifically on induction of FOLFIRINOX-based chemotherapy in 87 patients with BRPC, showed a promising 63% R0 resection rate without grade 4 toxicity. 52 Studies have shown a significantly decreased rate of lymph node involvement 53, 54 and decreased postoperative morbidity, including a very low rate of pancreatic fistula complications. [53] [54] [55] Some series also suggest an improvement in survival. 53 
Predictive biomarkers to guide FOLFIRINOX use
Nowadays, no conclusive evidence has yet been obtained on predictive or monitoring tools to optimize PC chemotherapy. Candidates' micro RNA have been evaluated to predict the sensitivity/resistance to the drugs of FOLFIRINOX and GnP regimens, but data are still controversial. 61
Conclusion
Since 2011, the landscape of systemic treatment in MPC has significantly changed. FOLFIRINOX has emerged as the optimum initial approach for fit patients with a well-preserved PS. At present, the choice of initial chemotherapy regimen is still based on careful patient selection as no biomarkers in the tumor or blood can reliably predict patient response to FOLFIRINOX. Several publications report FOLFIRINOX as a potentially attractive regimen for induction treatment of BRPC patients, especially for cases with no option of entering a clinical trial. The R0 resection rates and survival rate observed in patients with LAPC treated with the FOLFIRINOX regimen are promising, marking the beginning of a new era in the treatment strategy of PC in appropriately selected patients.
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